|
March 27, 2012
The quest for 'radical' R&D innovation is often pursued at the expense of treatments with hidden blockbuster potential, writes Bert Spilker.
|
|
March 7, 2012
By:
Jennifer Ringler, Ben Comer
Jim Currie and Baber Ghauri talk to Pharm Exec about making connections that resonate with audiences in a digital world.
|
January 1, 2012
By:
Bill Drummy
It's a disturbing irony: In an industry whose entire economic value is founded on its ability to innovate, why is there so much discomfort with the risk required for innovation. Where did the courage to innovate go?
|
|
January 1, 2012
By:
Ben Comer
A selection of the recent breakthrough technologies showcased at the Cleveland Clinic's Medical Innovations Summit.
|
|
January 1, 2012
By:
William Looney
The challenge for 2012 is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap.
|
|
January 1, 2012
By:
Julian Upton
Pharma has become unusually quick to strike embrace the iPad. But the industry's inherent conservatism means it has some way to go to fully milk the device's potential.
|
|
December 1, 2011
By:
Ben Comer
It's a neck and neck race toward safer, faster, and medically superior treatments. Which organizations have what it takes to jockey their products into the winner's circle?
|
|
September 1, 2011
By:
Julian Upton
Especially when payers come to the table holding the best cards — leaving industry second-guessing its strategy.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
